- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Structure Therapeutics Inc ADR (GPCR)
Structure Therapeutics Inc ADR stock price live, this page displays NASDAQ GPCR stock exchange data. View the GPCR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Structure Therapeutics Inc ADR real time stock price chart below.
What Is the Structure Therapeutics Inc ADR Stock Price Today?
The Structure Therapeutics Inc ADR stock price today is 75.21.
What Is the Stock Symbol for Structure Therapeutics Inc ADR?
The stock symbol for Structure Therapeutics Inc ADR is "GPCR."
What Stock Exchange Does Structure Therapeutics Inc ADR Trade On?
Structure Therapeutics Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Structure Therapeutics Inc ADR a Good Stock to Buy?
Determining whether Structure Therapeutics Inc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GPCR quote. (ISIN: US86366E1064)
What Is the Structure Therapeutics Inc ADR Stock Price Today?
The Structure Therapeutics Inc ADR stock price today is 75.21.
What Is the Stock Symbol for Structure Therapeutics Inc ADR?
The stock symbol for Structure Therapeutics Inc ADR is "GPCR."
What Stock Exchange Does Structure Therapeutics Inc ADR Trade On?
Structure Therapeutics Inc ADR is listed and trades on the NASDAQ stock exchange.
Is Structure Therapeutics Inc ADR a Good Stock to Buy?
Determining whether Structure Therapeutics Inc ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GPCR quote. (ISIN: US86366E1064)
NASDAQ
Currency in USD
75.21
+2.00(+2.73%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
72.27
76.08
52 wk Range
13.22
94.90
GPCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
72.2776.08
52 wk Range
13.2294.90
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GPCR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
107.80
Upside
+43.33%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Structure Therapeutics Inc ADR Company Profile
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Structure Therapeutics Inc ADR SWOT Analysis
Oral GLP-1 Pionee | Structure Therapeutics leads the charge in developing oral treatments for diabetes and obesity, with aleniglipron showing promise in the competitive GLP-1 market |
Pipeline Potential | Explore GPCR's robust pipeline, including aleniglipron and ACCG-2671, poised to disrupt the metabolic disease treatment landscape with oral formulations |
Market Dynamics | Delve into Structure Therapeutics' strategic positioning amidst fierce competition from pharma giants, leveraging its focus on oral small molecule therapies |
Financial Outlook | Analyst price targets range from $37.50 to $120 per share, reflecting optimism about GPCR's potential in the expanding GLP-1 receptor agonist market |
Compare GPCR to Peers and Sector
Metrics to compare | GPCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGPCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −24.4x | −4.4x | −0.5x | |
PEG Ratio | 0.37 | −0.07 | 0.00 | |
Price/Book | 6.7x | 1.6x | 2.6x | |
Price / LTM Sales | - | 8.1x | 3.3x | |
Upside (Analyst Target) | 37.7% | 163.4% | 48.1% | |
Fair Value Upside | Unlock | 9.3% | 7.7% | Unlock |
Analyst Ratings
15 Buy
0 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 107.80
(+43.33% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.37 / -0.27
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Structure Therapeutics ADR (GPCR) Stock Price Today?
The Structure Therapeutics ADR stock price today is 75.21
What Stock Exchange Does Structure Therapeutics ADR Trade On?
Structure Therapeutics ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Structure Therapeutics ADR?
The stock symbol for Structure Therapeutics ADR is "GPCR."
What Is the Structure Therapeutics ADR Market Cap?
As of today, Structure Therapeutics ADR market cap is 5.06B.
What Is Structure Therapeutics ADR's Earnings Per Share (TTM)?
The Structure Therapeutics ADR EPS (TTM) is -3.65.
When Is the Next Structure Therapeutics ADR Earnings Date?
Structure Therapeutics ADR will release its next earnings report on Mar 26, 2026.
From a Technical Analysis Perspective, Is GPCR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Structure Therapeutics ADR Stock Split?
Structure Therapeutics ADR has split 0 times.
How Many Employees Does Structure Therapeutics ADR Have?
Structure Therapeutics ADR has 218 employees.
What is the current trading status of Structure Therapeutics ADR (GPCR)?
As of Feb 07, 2026, Structure Therapeutics ADR (GPCR) is trading at a price of 75.21, with a previous close of 73.21. The stock has fluctuated within a day range of 72.27 to 76.08, while its 52-week range spans from 13.22 to 94.90.
What Is Structure Therapeutics ADR (GPCR) Price Target According to Analysts?
The average 12-month price target for Structure Therapeutics ADR is USD107.80, with a high estimate of USD140 and a low estimate of USD90. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +43.33% Upside potential.
What Is the GPCR Premarket Price?
GPCR's last pre-market stock price is 74.50. The pre-market share volume is 5,860.00, and the stock has decreased by 1.29, or 1.76%.
What Is the GPCR After Hours Price?
GPCR's last after hours stock price is 72.00, the stock has decreased by -1.21, or -1.65%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.